Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.30 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL975346 | 0.87 | ABCB11 (0.37) | AGTR1ALDH1A1MAPTHPGD | |
| SCHEMBL976867 | 0.86 | MME (0.36) | MMEAGTR1ALDH1A1MAPTHPGD | |
| SCHEMBL976860 | 0.85 | AGTR1 (0.31) | MMEAGTR1PARP1S1PR1S1PR3 | |
| SCHEMBL976884 | 0.85 | CTSA (0.34) | ALDH1A1CTSA | |
| SCHEMBL975052 | 0.84 | ALDH1A1 (0.34) | ALDH1A1MAPTHPGD | |
| SCHEMBL976879 | 0.84 | AGTR1 (0.36) | MMEAGTR1 | |
| SCHEMBL978177 | 0.84 | PARP1 (0.32) | MMEAGTR1PARP1S1PR1S1PR3 | |
| SCHEMBL977501 | 0.77 | MAPT (0.36) | MMEAGTR1ALDH1A1MAPTHPGD | |
| SCHEMBL976309 | 0.73 | CTSA (0.34) | MMEAGTR1ALDH1A1CTSA | |
| SCHEMBL976876 | 0.73 | AGTR1 (0.38) | AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181206-B2 | Dual-acting oxazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140194426-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8598170-B2 | Dual-acting oxazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2456762-B1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE INC (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20130196997-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-08-01 | — | — | US | disclosed |
| US-8372984-B2 | Dual-acting oxazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2456762-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | Theravance, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20110021527-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-01-27 | — | — | US | disclosed |
| WO-2011011232-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021527-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | MME 5/4885AGTR1 1/4885ALDH1A1 2176/4885 |
| US-20130196997-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | MME 5/4885AGTR1 1/4885ALDH1A1 2176/4885 |
| US-20140194426-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | MME 5/4885AGTR1 1/4885ALDH1A1 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.